Meeting
2024 ASCO Genitourinary Cancers Symposium
Enfortumab vedotin (EV) in cisplatin-eligible and ineligible patients with advanced urothelial cancer (aUC): A single-center experience.
Authors
Evangelia Vlachou
Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD
Evangelia Vlachou , Burles Avner Johnson III, Roy Elias , Noah M. Hahn , David James McConkey , Jean H. Hoffman-Censits
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 569)
DOI
10.1200/JCO.2024.42.4_suppl.569
Abstract #
569
Poster Bd #
E18
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Outcomes of enfortumab vedotin (EV) therapy in relation to prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial cancer (aUC).
First Author: Evangelia Vlachou
Poster
2024 ASCO Genitourinary Cancers Symposium
Evolving treatment landscape in metastatic urothelial carcinoma (mUC) post-avelumab maintenance approval: Real-world insights from The US Oncology Network.
First Author: Haojie Li
Poster
2023 ASCO Annual Meeting
Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.
First Author: Thomas W. Flaig
Poster
2020 ASCO Virtual Scientific Program
Pembrolizumab (pembro) versus standard of care chemotherapy (chemo) in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.
First Author: Hironaga Satake